Plus   Neg

Tetraphase Pharmaceuticals (TTPH) Plunged To A New Low After Study Failed

Tetraphase Pharmaceuticals (TTPH) announced after the close Tuesday that its Phase 3 study of once-daily intravenous eravacycline compared to ertapenem for the treatment of patients with complicated urinary tract infections did not achieve it co-primary endpoints.

Tetraphase Pharmaceuticals gapped open sharply lower Wednesday and declined until mid-morning. The stock was range-bound for the rest of the session and closed down by 3.28 at $2.15 on the highest volume of the year. Tetraphase Pharmaceuticals plunged to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

$5 And Under

0 Articles
Follow RTT